Cathie Wood’s ARK sells DraftKings stock and buys CRISPR Therapeutics

ARK ETFs sold 397,016 DraftKings shares for approximately $7.89 million and 57,911 CareDx shares for $3.60 million on October 9, 2026. ARK also bought shares in several biotech companies, including CRISPR Therapeutics ($1.08 million), Guardant Health ($1.19 million) and Nurix Therapeutics ($1.24 million), reflecting mixed fund-level positioning rather than a single directional market signal.

Analysis

The useful signal is positioning, not a change in operating outlook. Repeated DKNG and CDNA selling could add a modest near-term supply overhang if other ARK funds follow, but without fund AUM, ownership, trading-volume context, and subsequent flow data, these prints do not establish meaningful pressure or informed negative views. Likewise, buying CRSP, GH, NRIX, and NTLA may support sentiment across innovation-biotech names, but it is not evidence of improved trial prospects, reimbursement, or financing conditions. A second-order effect is potential relative-flow divergence among high-beta biotech stocks; fundamentals and clinical catalysts should dominate over a 6–18 month horizon. The contrarian read: investors may overinterpret daily ETF disclosures as conviction signals when routine rebalancing and cash management can produce the same pattern. In the next 1–3 months, persistence of net flows matters more than this single session. Verify the reported SPCX instrument and transaction details before treating that print as investable-market evidence.

Key Decisions for Investors

• No trade on this disclosure alone. Do not infer a DKNG or CDNA fundamental downgrade from ARK sales; reassess only if subsequent filings or flow data show sustained, material selling relative to fund ownership and normal liquidity.
• Treat CRSP, NTLA, GH, and NRIX purchases as a sentiment watchlist, not a biotech basket signal. Require company-specific clinical, regulatory, or commercial catalysts before adding exposure; trial setbacks or financing needs can overwhelm ETF demand.
• For a 1–3 month positioning check, monitor ARK fund flows and repeat trade disclosures alongside DKNG trading volume and company guidance. A reversal to sustained buying would weaken the supply-overhang thesis; continued selling with unusually high turnover would strengthen it.
• Validate the SPCX instrument, listing status, and reported trade against an independent source before using it in any portfolio or liquidity analysis.